UPDATE 1-Temasek-backed Tychan to start human trials next week for COVID-19 treatment
Singapore’s Tychan, a
biotechnology firm backed by state investor Temasek Holdings,
said it will begin human clinical trials next week for a
potential monoclonal antibody treatment for COVID-19.
biotechnology firm backed by state investor Temasek Holdings,
said it will begin human clinical trials next week for a
potential monoclonal antibody treatment for COVID-19.
Posted by Reuters
